12-0666-42

antibody from Invitrogen Antibodies

Targeting: CEACAM8 CD66b, CGM6

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

12-0666-42

Provider

Invitrogen Antibodies

Product name

CD66b Monoclonal Antibody (G10F5), PE, eBioscience™

Antibody type

Monoclonal

Antigen

Other

Description

Description: This G10F5 monoclonal antibody reacts with human CD66b, one of four members of the CD66 family of granulocyte-specific activation antigens. Expressed on neutrophils and eosinophils, CD66b is upregulated following stimulation. This glycosyl-phosphatidylinositol-linked cell surface receptor plays a role in regulating neutrophil activation and adhesion to fibronectin, galectin-3, and E-selectin. Applications Reported: This G10F5 antibody has been reported for use in flow cytometric analysis. Applications Tested: This G10F5 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.125 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.

Reactivity

Human

Host

Mouse

Conjugate

Yellow dye

Isotype

IgM

Antibody clone number

G10F5

Vial size

100 Tests

Concentration

5 µL/Test

Storage

4°C, store in dark, DO NOT FREEZE!

References

Submitted references

Distinct clinical and immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa.

Morton B, Barnes KG, Anscombe C, Jere K, Matambo P, Mandolo J, Kamng'ona R, Brown C, Nyirenda J, Phiri T, Banda NP, Van Der Veer C, Mndolo KS, Mponda K, Rylance J, Phiri C, Mallewa J, Nyirenda M, Katha G, Kambiya P, Jafali J, Mwandumba HC, Gordon SB, Blantyre COVID-19 Consortium, Cornick J, Jambo KC
Nature communications 2021 Jun 11;12(1):3554

---

Loss of testosterone impairs anti-tumor neutrophil function.

Markman JL, Porritt RA, Wakita D, Lane ME, Martinon D, Noval Rivas M, Luu M, Posadas EM, Crother TR, Arditi M
Nature communications 2020 Mar 31;11(1):1613

---

A FACS-based approach to obtain viable eosinophils from human adipose tissue.

Hernandez JD, Tew BY, Li T, Gooden GC, Ghannam H, Masuda M, Madura J 2nd, Salhia B, Jacobsen EA, De Filippis E
Scientific reports 2020 Aug 6;10(1):13210

---

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

Labuhn M, Perkins K, Matzk S, Varghese L, Garnett C, Papaemmanuil E, Metzner M, Kennedy A, Amstislavskiy V, Risch T, Bhayadia R, Samulowski D, Hernandez DC, Stoilova B, Iotchkova V, Oppermann U, Scheer C, Yoshida K, Schwarzer A, Taub JW, Crispino JD, Weiss MJ, Hayashi Y, Taga T, Ito E, Ogawa S, Reinhardt D, Yaspo ML, Campbell PJ, Roberts I, Constantinescu SN, Vyas P, Heckl D, Klusmann JH
Cancer cell 2019 Aug 12;36(2):123-138.e10

---

Lipopolysaccharides from Microcystis Cyanobacteria-Dominated Water Bloom and from Laboratory Cultures Trigger Human Immune Innate Response.

Moosová Z, Šindlerová L, Ambrůzová B, Ambrožová G, Vašíček O, Velki M, Babica P, Kubala L
Toxins 2019 Apr 11;11(4)

---

Tumor cell-released autophagosomes (TRAP) enhance apoptosis and immunosuppressive functions of neutrophils.

Gao R, Ma J, Wen Z, Yang P, Zhao J, Xue M, Chen Y, Aldarouish M, Hu HM, Zhu XJ, Pan N, Wang LX
Oncoimmunology 2018;7(6):e1438108

---

Neonatal myeloid derived suppressor cells show reduced apoptosis and immunosuppressive activity upon infection with Escherichia coli.

Leiber A, Schwarz J, Köstlin N, Spring B, Fehrenbach B, Katava N, Poets CF, Gille C
European journal of immunology 2017 Jun;47(6):1009-1021

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Staining of normal human peripheral blood cells with Mouse IgM Isotype Control PE (Product # 12-4752) (blue histogram) or Anti-Human CD66b PE (purple histogram). Cells in the granulocyte gate were used for analysis.

Conjugate

Yellow dye

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Staining of normal human peripheral blood cells with Mouse IgM Isotype Control PE (Product # 12-4752) (blue histogram) or Anti-Human CD66b PE (purple histogram). Cells in the granulocyte gate were used for analysis.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 5 Analysis of neutrophils from control or androgen deprivation therapy (ADT) treated patients. a Percent of circulating neutrophils from control or ADT treated prostate cancer patients that have a mature, segmented appearance morphologically. b Percent Cd11b + CD66b + CD16 lo neutrophils. c Percent myeloid derived suppressor cell (MDSC)-like neutrophils defined as HLA-DR - CD14 - CD33 + CD15 + . d Percent fold change in migration (percent crystal violet positive area of transwell stimulated with a chemoattractant divided by percent area without chemoattractant). e Percent of unstimulated neutrophils producing DHR123. f Percent of neutrophils producing DHR123 following PMA stimulation. g Percent myeloperoxidase + (MPO + ) neutrophils. h Percent of plated netosising neutrophils at 1 and 3 h following purification. Data in a - h are mean +- s.e.m., * p < 0.05, ** p < 0.01, *** p < 0.001 by multivariable linear regression using ADT as its main predictor and adjusting for presence of prostatectomy, age, race, and current status; control prostate cancer patients ( n = 8 in a , c , g and n = 7 in b , d , e , f , h ) and prostate cancer pati e nts receiving ADT ( n = 22 in a , c , g and n = 21 in b , d , e , f , h ).

Conjugate

Yellow dye